European Vision Institute Clinical Research Network   Report issue

Academic/Hospital Phase 3 Phase 4
Founded: Coimbra Portugal (2010)

Organization Overview

First Clinical Trial
2013
NCT01975714
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (4)

aflibercept (zaltrap) (1 trial)

bimatoprost (lumigan) (1 trial)

latanoprost (xalatan) (1 trial)

verteporfin (visudyne) (1 trial)

Drugs in Phase 3 Trials (1)

ranibizumab (lucentis) (1 trial)

Drugs in Other Trials (1)

ozurdex (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Retinopathy (Phase 3)

Glaucoma (Phase 4)

Hypertension (Phase 4)

Ocular Hypertension (Phase 4)

Retinal Diseases (Phase 3)

Vascular Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 6